Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of JMKX005425 in Patients With MSI-H/dMMR Advanced Solid Tumors
Sponsor: Jemincare
Summary
This is a first-in-human, Phase I, open-label, multi-center, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of JMKX005425 in subjects with microsatellite instability-high (MSI) and/or mismatch repair deficiency (dMMR) advanced solid tumors.
Official title: An Open-label, Multi-center Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of JMKX005425 Tablets in Subjects With Microsatellite Instability-High or Mismatch Repair Deficient Advanced Solid Tumors
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
102
Start Date
2025-10-22
Completion Date
2028-12
Last Updated
2025-12-01
Healthy Volunteers
No
Conditions
Interventions
JMKX005425
JMKX005425 administered orally.
Locations (1)
Beijing Cancer Hospital
Beijing, China